Shanxi C&Y Pharmaceutical Group Co Ltd Total Liabilities
Shanxi C&Y Pharmaceutical Group Co Ltd total liabilities. Based on the latest financial reports, Shanxi C&Y Pharmaceutical Group Co Ltd (300254) has total liabilities worth CN¥1.00 Billion CNY (≈ $146.58 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 300254 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Shanxi C&Y Pharmaceutical Group Co Ltd (2008–2025)
Total liabilities of Shanxi C&Y Pharmaceutical Group Co Ltd from 2008 to 2025. This chart illustrates how Shanxi C&Y Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Shanxi C&Y Pharmaceutical Group Co Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
Shanxi C&Y Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shanxi C&Y Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ainsworth Game Technology Ltd
AU:AGI
|
Australia | AU$107.49 Million |
|
Chongqing New Dazheng Property Grp
SHE:002968
|
China | CN¥711.44 Million |
|
Hangzhou Todaytec Digital Co Ltd Class A
SHE:300743
|
China | CN¥400.77 Million |
|
Marshall Boya ve Vernik Sanayi AS
IS:MRSHL
|
Turkey | TL3.06 Billion |
|
Hubei Forbon Technology Co Ltd
SHE:300387
|
China | CN¥561.81 Million |
|
Sight Sciences Inc
NASDAQ:SGHT
|
USA | $51.97 Million |
|
Zhejiang Canaan Technology Co Ltd
SHE:300412
|
China | CN¥1.41 Billion |
|
Vátryggingafélag Íslands hf
IC:SKAGI
|
Iceland | Ikr44.30 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Shanxi C&Y Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 300254 asset base.
Liquidity & Leverage Metrics
Shanxi C&Y Pharmaceutical Group Co Ltd Total Liabilities Ratios Explained
Shanxi C&Y Pharmaceutical Group Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanxi C&Y Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanxi C&Y Pharmaceutical Group Co Ltd (2008–2025)
The table below shows the annual total liabilities of Shanxi C&Y Pharmaceutical Group Co Ltd from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.05 Billion ≈ $153.39 Million |
+10.40% |
| 2024-12-31 | CN¥949.55 Million ≈ $138.95 Million |
+45.05% |
| 2023-12-31 | CN¥654.64 Million ≈ $95.79 Million |
-23.40% |
| 2022-12-31 | CN¥854.64 Million ≈ $125.06 Million |
+9.26% |
| 2021-12-31 | CN¥782.23 Million ≈ $114.46 Million |
-15.70% |
| 2020-12-31 | CN¥927.91 Million ≈ $135.78 Million |
+6.73% |
| 2019-12-31 | CN¥869.43 Million ≈ $127.22 Million |
+54.03% |
| 2018-12-31 | CN¥564.47 Million ≈ $82.60 Million |
+3.11% |
| 2017-12-31 | CN¥547.42 Million ≈ $80.10 Million |
+14.59% |
| 2016-12-31 | CN¥477.74 Million ≈ $69.91 Million |
+9.59% |
| 2015-12-31 | CN¥435.93 Million ≈ $63.79 Million |
+21.71% |
| 2014-12-31 | CN¥358.17 Million ≈ $52.41 Million |
+10.82% |
| 2013-12-31 | CN¥323.21 Million ≈ $47.30 Million |
+83.65% |
| 2012-12-31 | CN¥175.99 Million ≈ $25.75 Million |
+44.98% |
| 2011-12-31 | CN¥121.39 Million ≈ $17.76 Million |
-7.51% |
| 2010-12-31 | CN¥131.25 Million ≈ $19.21 Million |
-7.51% |
| 2009-12-31 | CN¥141.91 Million ≈ $20.77 Million |
+20.82% |
| 2008-12-31 | CN¥117.45 Million ≈ $17.19 Million |
-- |
About Shanxi C&Y Pharmaceutical Group Co Ltd
ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, smoking cessation drugs, pediatric drugs, respiratory system drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, nephropathy drugs, anti-depressant… Read more